Product Description
CID-078 is an orally bioavailable macrocycle with dual cyclin A and B inhibitory activity that drives synthetic lethality in multiple tumor types. In biochemical and cellular studies, CID-078 has been shown to potently and selectively disrupt the protein-protein interaction between Cyclins A and B and their key substrates, including E2F (a substrate of Cyclin A) and Myt1 (a substrate of Cyclin B). Preclinical studies have demonstrated the ability of CID-078 to cause pronounced tumor regression in multiple xenograft models. Circle Pharma plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for CID-078 and initiate clinical development in 2024. (Sourced from: https://www.benzinga.com/pressreleases/23/07/b33281591/circle-pharma-achieves-major-milestone-with-the-selection-of-a-clinical-development-candidate-dire)
Mechanisms of Action: CCNA1 Inhibitor, CCNB1
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Small Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Circle Pharma
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lung Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Triple Negative Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06577987 |
CID-AB1-24001 | P1 |
Recruiting |
Triple Negative Breast Cancer|Neuroendocrine Tumors|Neuroendocrine Carcinoma|Lung Cancer |
2027-01-14 |
12% |
2025-05-24 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/18/2026 |
News Article |
Circle Pharma to Present New Clinical and Preclinical Data at AACR 2026 |
|
03/12/2026 |
News Article |
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors |
|
01/05/2026 |
News Article |
Circle Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference |
|
12/17/2025 |
News Article |
Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program |